08/07/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by a limited number of investors Download PDF Post navigationPreviousPrevious post:Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefitNextNext post:AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALSRelated PostsAB Science announces the successful completion of a 2.8 million euros private placementOctober 17, 2025Summary of the virtual conference held on October 16, 2025October 16, 2025AB Science webcast of October 16, 2025October 16, 2025AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939October 14, 2025Revenues for the first half of 2025 and update on AB Science’s activitiesOctober 10, 2025AB Science announces a slight delay in the publication of its 2025 half-year financial reportSeptember 30, 2025
AB Science announces the successful completion of a 2.8 million euros private placementOctober 17, 2025
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939October 14, 2025
AB Science announces a slight delay in the publication of its 2025 half-year financial reportSeptember 30, 2025
